Clinical Trial Update: Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing first-line treatment with lenvatinib plus tislelizumab and CapeOX for advanced gastric/gastroesophageal junction cancer in PD-L…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Eloxatin (oxaliplatin)
• LENVIMA (lenvatinib)
• Tislelizumab (tislelizumab)
• Xeloda (capecitabine)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Gastric Cancer | Phase 2 | Status: RECRUITING